KB-1336

1K17-044-hIgG1

Home » Antibody » 1K17-044-hIgG1

Background

CCR8 is a member of the chemokine receptor family and functions as a G-protein coupled receptor. Extensive research has revealed that CCR8 exhibits specific expression on regulatory T cells (Treg) infiltrating tumors, as well as on Th2 cells and tumor cells. The monoclonal antibody 1K17-044-hIgG1, currently under development as an anti-CCR8 therapeutic, has demonstrated the capacity to induce discernible depletion of CCR8+ Treg cells in human tumor explants. This CCR8+ Treg depletion has translated into robust antitumor activity when administered as a standalone treatment and in combination with anti-PD-1 therapy in murine tumor models. These findings provide substantial support for further clinical exploration of CCR8 depletion, especially in conjunction with immune checkpoint blockade, as an innovative approach to cancer immunotherapy.

Specifications

Catalog Number:
KB-1336
Cell Line Name:
1K17-044-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CCR8
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.PB Silver, et al., Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J Immunol 194, 3011¨C3019 (2015). 2.J van Loosdregt, et al., Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 39, 259¨C271 (2013).
Please enable JavaScript in your browser to complete this form.